Insider buying last 90 days
No open-market insider purchases were filed for STAA in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every STAA insider filing, plotted on the chart in Gekko.Open STAA in Gekko
NASDAQ: STAA
STAAR Surgical (STAA) Stock Analysis & Forecast
Oct 12 close
$22.01+0.34 (+1.6%)
Gekko Brief
AI summaryOct 12 closeSTAAR Surgical appointed Andrew Pilon, OD, previously of Johnson & Johnson Vision, as Vice President of Business Development, with coverage pointing to his focus on partnerships, acquisitions and licensing to expand the product portfolio. Separately, commentary this week revisited STAAR's quarter, noting 111% year-on-year revenue growth that exceeded analyst expectations and the biggest analyst estimate beat among medical devices and supplies peers, alongside continued questions about valuation after a five-year share price decline of 81.6%.
STAA closed at $22.01, up 1.6%, but remains below both its 50-day average of $22.87 and 200-day average of $23.60, with the 50-day also below the 200-day. Shares are down 2.9% over one month, 19.5% over three months and 15.9% over the past year, against a 52-week range of $15.59 to $35.87. The GekkoIndex reads 58.9, placing the stock in the Neutral zone, up 3.9 over five sessions. Price sits 11.8% below Gekko Fair Value of $24.95.
The next earnings date is 4 November 2026, after the close, 23 days away and inside a typical 20-trading-day holding window; the prior quarter saw EPS of $0.01 against a $0.15 estimate with a 2.9% reaction. No insider, Congress or unusual options activity appears in their respective windows. Seasonally, the next 20 trading days have averaged -5.8% over 5 years, higher in just 1 of them. Analyst consensus among 9 firms shows 3 buy, 5 hold and 1 sell ratings, with a consensus target of $28.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
STAAR Surgical price vs fair value
Close $22.01200-day averageGekko Fair Value $24.95
STAAR Surgical quick facts
- Market cap
- $1.10B
- P/E ratio
- 279.8
- Forward P/E
- 62.5
- EPS, TTM
- $0.08
- Revenue, TTM
- $339.6M
- Profit margin
- 1.1%
- Dividend yield
- —
- Beta
- 1.18
- Volume
- 596,010 avg 1.05M
- 1-year return
- −15.9%
- Typical daily move
- ±4.5%
- Typical 20-day move
- ±10.6%
- 50-day average
- $22.87
- 200-day average
- $23.60
- Next earnings
- Nov 4 after close
- Shares outstanding
- 50.14M
STAAR Surgical swing-trade checklist
STAAR Surgical scores 1 supportive, 1 mixed and 3 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
1 supportive1 mixed3 headwinds
- Trendheadwind
Below 50 and 200-day
Close $22.01 is below the 50-day ($22.87) and 200-day ($23.60) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexmixed
58.9, Neutral
Reading 58.9 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
11.8% below
Price is 11.8% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 23 days
Reports on Nov 4, 2026, 23 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−5.8% on average
From this point in the calendar, the next 20 trading days averaged −5.8% over 5 years, rising in 1 of them.
See seasonality
A description of current data, not a recommendation. How this page works
STAAR Surgical stock chart and price history
STAAR Surgical closed at $22.01 on Oct 12, 2026, −15.9% over the past year, inside a 52-week range of $15.59 to $35.87.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −2.9%
- 3 months
- −19.5%
- 6 months
- −18.0%
- 1 year
- −15.9%
The full STAA chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open STAA in Gekko
Follow STAAR Surgical through every session
Put STAA on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track STAA in GekkoFree for 7 days. No credit card required.
About STAAR Surgical
STAAR Surgical develops lenses that correct vision, along with the delivery systems surgeons use to implant them. Its best-known line is the Visian implantable Collamer lens, used to treat nearsightedness, farsightedness, astigmatism and the age-related loss of near focus known as presbyopia, with a dedicated version aimed specifically at hyperopia. Beyond these implantable lenses, the company also makes preloaded silicone intraocular lenses and their injector systems for cataract procedures, plus related injector parts and other surgical instruments.
Its customers include ophthalmic surgeons, eye and surgical clinics, hospitals, public health facilities and distributors, with ophthalmologists as the primary end users of the products. In the United States, Japan, Germany, Spain, Canada, the United Kingdom and Singapore, STAAR Surgical sells through its own sales staff, while in markets such as China, Korea, India, France, the Benelux countries and Italy it relies on a combination of direct representatives and outside distributors.
The company was founded in 1982 and is headquartered in Lake Forest, California. Its shares are listed on the NASDAQ under the ticker STAA.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- staar.com
STAAR Surgical GekkoIndex: the smart money zone
STAAR Surgical’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 58.9, in the Neutral zone, up 3.9 points over five sessions.
58.9Neutral
Up 3.9 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 44 | +3.4% | +3.3% | ||
| Accumulation | 302 | −0.9% | −2.9% | ||
| Neutral (current zone) | 301 | +1.0% | +4.0% | ||
| Distribution | 28 | −3.2% | −7.2% | ||
| Selling | 7 | Too few readings yet | |||
Average STAA share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the STAA price, zone by zone.Track STAA in Gekko
Is STAAR Surgical stock overvalued? Gekko Fair Value
STAAR Surgical trades 11.8% below Gekko Fair Value of $24.95, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what STAAR Surgical shares are worth, recalculated every trading day.
$24.95
Gekko Fair Value, Oct 10, 2026
11.8% Undervalued
At the end of Aug 2026 the price was 16.6% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open STAA in Gekko
STAAR Surgical insider and Congress trading
No open-market insider purchases were filed for STAAR Surgical, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in STAA were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for STAA, plotted on the chart in Gekko.Open STAA in Gekko
Buybacks
STAAR Surgical has been buying back its own shares.
- Bought back, quarter ended Jul 3, 2026
- $2.74M
- As a share of market cap
- 0.25%
- Trailing four quarters
- $6.75M
From company filings.
Hedge funds and billionaires quarter ended Dec 31
0of the funds Gekko tracks hold STAA.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
STAAR Surgical earnings: next date and track record
STAAR Surgical reports on Nov 4, 2026, after the close (23 days away), and beat the EPS estimate in 3 of its last 8 reports.
Next earnings report
Nov 4, 2026
Expected after the close, 23 days away
- EPS estimate
- $0.05
- Revenue estimate
- $78.74M
3 of 8reports beat the EPS estimate
±4.2%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Feb 25, 2026 AI summary
- What they said
- STAAR Surgical reported Q4 2025 results with new interim Co-CEOs Warren Foust and Deborah Andrews leading the company. China, their largest market, saw mid-single-digit EVO ICL demand recovery despite distributors reducing inventory levels, preventing net sales growth in 2025. The company expects 2026 to be a growth year with improving profitability and innovation pipeline progress, supported by the expanded U.S. age range indication for EVO ICL (now approved for ages 21-60).
- Guidance
- Management expects 2026 to be a much better year with growth, improving profitability, and meaningful innovation pipeline progress. They are optimistic about China market rebound and continued momentum in the U.S. business.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Feb 25, 2026 | $0.01 est $0.15 | $57.80M est $74.96M | +2.9% |
| Oct 29, 2025 | $0.16 est $0.21 | $94.73M est $75.54M | −2.3% |
| Aug 6, 2025 | −$0.07 est −$0.56 | $44.32M est $89.15M | −0.3% |
| May 7, 2025 | −$0.52 est −$0.59 | $42.59M est $40.30M | +4.8% |
| Feb 19, 2025 | −$0.69 est −$0.03 | — | +1.3% |
| Oct 30, 2024 | $0.20 est $0.18 | $88.59M est $77.84M | −4.3% |
| Aug 7, 2024 | $0.15 est $0.24 | $99.01M est $95.20M | +6.5% |
| May 7, 2024 | −$0.07 est $0.03 | $77.36M est $74.91M | −10.8% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
STAAR Surgical stock forecast and analyst price targets
Analysts’ average 12-month price target for STAAR Surgical is $28.00, +27.2% from the last close, from 9 firms rating the stock in the last 90 days.
$28.00consensus 12-month target, +27.2% from the last close
Now $22.01Avg $28.00
Low $20High $40
Each firm’s latest rating in the last 90 days: 9 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 29 | Stifel Nicolaus | $31 | +40.8% |
| Sep 24 | Canaccord Genuity | $32 | +45.4% |
| Sep 22 | Jefferies | $23 | +4.5% |
| Aug 17 | Stifel Nicolaus | $28 | +27.2% |
| Aug 13 | Needham | — | — |
+4.0%average 20-day move after past Neutral readings
−5.8%average move over the next 20 trading days in the last 5 years
±4.5%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
STAAR Surgical seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, STAAR Surgical averaged −5.8% across the last 5 years, rising in 1 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.8% | 4 of 5 |
| Next 10 trading days | +1.4% | 3 of 5 |
| Next 15 trading days | +0.1% | 2 of 5 |
| Next 20 trading days | −5.8% | 1 of 5 |
| Next 30 trading days | −10.4% | 1 of 5 |
For scale, STAA’s typical 20-trading-day move in either direction is about 10.6%.
STAAR Surgical market cap and key statistics
STAAR Surgical’s market cap is $1.10B, with a P/E ratio of 279.8 and revenue of $339.6M over the last twelve months.
Valuation
- Market cap
- $1.10B
- P/E ratio
- 279.8
- Forward P/E
- 62.5
- EPS, TTM
- $0.08
- Gekko Fair Value
- $24.95
Trading
- Volume
- 596,010
- Avg volume, 20 days
- 1.05M
- 52-week high
- $35.87
- 52-week low
- $15.59
- Shares outstanding
- 50.14M
Financials
- Revenue, TTM
- $339.6M
- Profit margin
- 1.1%
- Return on equity
- 1.1%
- Quarterly earnings growth, YoY
- −10.5%
Risk and income
- Beta
- 1.18
- Typical daily move
- ±4.5%
- Typical 20-day move
- ±10.6%
STAAR Surgical stock news this week
Coverage of STAAR Surgical this week reads positive: 7 positive, 2 neutral and 0 negative headlines.
- STAAR Surgical (STAA) Stock Could Be Cheap As Shares Fell 82%Simply Wall Street, Oct 12
- STAAR Surgical Appoints Andrew Pilon, OD, as Vice President of Business DevelopmentVisionMonday.com, Oct 12
- STAAR Surgical (STAA) Posted A Standout Quarter, Is The Stock Cheap Enough?Simply Wall Street, Oct 9
- Winners And Losers Of Q2: STAAR Surgical (NASDAQ:STAA) Vs The Rest Of The Medical Devices & Supplies - Specialty StocksThe Globe and Mail, Oct 9
- STAAR Surgical names Andrew Pilon as VP of business developmentInvesting.com, Oct 8
- STAAR Surgical names Andrew Pilon as VP of business development By Investing.comInvesting.com Canada, Oct 8
STAAR Surgical peers
STAAR Surgical’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 18.2% above |
| ABTAbbott Laboratories | Neutral | 14.7% below |
| DHRDanaher | Neutral | 4.5% above |
| ISRGIntuitive Surgical | Neutral | 18.8% above |
| MDTMedtronic | Neutral | 22.9% below |
| SYKStryker | Accumulation | 12.6% below |
A peer links to its own page where one exists.
STAAR Surgical stock FAQ
What is STAAR Surgical’s market cap?
STAAR Surgical’s market cap is $1.10B at the Oct 12, 2026 close of $22.01, with 50.14M shares outstanding. The shares trade on a P/E ratio of 279.8.
What is the STAAR Surgical stock forecast?
The consensus analyst 12-month price target for STAAR Surgical is $28.00, +27.2% from the last close. Of the 9 firms that rated the stock in the last 90 days, 3 rate it a buy, 5 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
Is STAAR Surgical stock overvalued or undervalued?
On Gekko’s estimate STAAR Surgical is undervalued: the Oct 12, 2026 close of $22.01 is 11.8% below Gekko Fair Value of $24.95. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does STAAR Surgical report earnings next?
STAAR Surgical is expected to report on Nov 4, 2026, after the market closes (23 days away). Analysts expect earnings of $0.05 per share on revenue of $78.74M. STAAR Surgical beat the earnings estimate in 3 of its last 8 reports, moving 4.2% on average across the report.
What is STAAR Surgical’s 52-week high and low?
STAAR Surgical’s 52-week high is $35.87 and its 52-week low is $15.59; it closed at $22.01 on Oct 12, 2026, −15.9% over the past year. Over the last five years the shares peaked at $128.31 on Oct 21, 2021.
Is STAAR Surgical stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 1 of the 5 items with data read as supportive (fair value), 1 as mixed (gekkoindex) and 3 as headwinds (trend, earnings risk and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See STAAR Surgical the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.